Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Site Search
Showing 71 - 80 of 116 results
Press Release
|
|
4 min read
By educating elected officials and other government decision-makers on the needs of the cystic fibrosis community, the Cystic Fibrosis Foundation works to shape public policy to help our efforts to cure CF and provide all people with CF the opportunity to live full, healthy lives. Below find a listing of our state and federal statements, letters, and regulatory comments.
In 2022, the community’s determination helped us achieve new milestones and fueled our mission for a cure for all. Read our annual report to learn more about our achievements this year, and about our continued work toward helping people with cystic fibrosis live long, fulfilling lives.
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
Press Release
|
|
3 min read
Our vendors play a vital role in helping us fulfill our mission at the Cystic Fibrosis Foundation. As such, we aim to build mutually beneficial relationships with all our vendors while holding them to the same high standards we hold ourselves to. Learn more about these standards, and find other helpful documents and information.
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Press Release
|
|
4 min read
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
Press Release
|
|
3 min read
We hold ourselves accountable to our donors, volunteers, people with CF and their families, and the public. Learn about our governance and policies.
Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.
Press Release
|
|
3 min read
Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatment
Press Release
|
|
3 min read